Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/indapamide/telmisartan - George Medicines

Next Previous
Drug Profile

Amlodipine/indapamide/telmisartan - George Medicines

Alternative Names: GMRx2; Indapamide/amlodipine/telmisartan - George Medicines; Telmisartan/amlodipine/indapamide - George Medicines; WIDAPLIK

Latest Information Update: 09 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator George Medicines
  • Class Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Indoles; Ischaemic heart disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action ACE inhibitors; Angiotensin type 1 receptor antagonists; Angiotensin type 2 receptor antagonists; Calcium channel antagonists; Thiazide-like diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Hypertension
  • Phase III Haemorrhagic stroke

Most Recent Events

  • 02 Oct 2025 Amlodipine/indapamide/telmisartan is still in clinical trial for Hypertension in Nigeria (PO) (PACTR202107579572114)
  • 02 Oct 2025 George Medicines enters into a licensing agreement with Biolab Farmaceutica to commercialize GMRx2 (telmisartan, amlodipine and indapamide) in Brazil
  • 28 Sep 2025 No recent reports of development identified for clinical-Phase-Unknown development in Hypertension in Nigeria (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top